Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study
Our preliminary data show that step-down therapy with mepolizumab to 100 mg/4 weeks was effective in maintaining systemic remission and reducing GC use in EGPA patients. However, recurrence of sinonasal symptoms suggests the need for an individualized management. Larger studies are warranted to confirm these findings and optimize dosing strategies for long-term care.
Authors
- Gabriele Gallina (ORCID: https://orcid.org/0000-0003-4285-5966)
- Umberto Tanzini
- Lorenzo Dagna (ORCID: https://orcid.org/0000-0002-7428-315X)
- Giulia Danè (ORCID: https://orcid.org/0009-0003-7905-7260)
- Marco Matucci‐Cerinic (ORCID: https://orcid.org/0000-0002-9324-3161)
- Maria Bernadette Cilona (ORCID: https://orcid.org/0000-0003-3677-4342)
- Adriana Cariddi
- Giovanni Benanti (ORCID: https://orcid.org/0000-0002-4310-6951)
- Luca Moroni (ORCID: https://orcid.org/0000-0001-8988-9106)
- Marco Lanzillotta (ORCID: https://orcid.org/0000-0002-4522-2921)
- Batani Veronica
Institutions
- University of Modena and Reggio Emilia (IT)
- Vita-Salute San Raffaele University (IT)
- IRCCS Ospedale San Raffaele (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1093/rheumatology/keaf201
- Citations
- 3
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 4.56